Difference between revisions of "Apocrine carcinoma of the breast"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 1: | Line 1: | ||
{{ Infobox diagnosis | {{ Infobox diagnosis | ||
| Name = {{PAGENAME}} | | Name = {{PAGENAME}} | ||
| Image = | | Image = Breast ApocrineCarcinoma MP2 CTR.jpg | ||
| Width = | | Width = | ||
| Caption = | | Caption = Apocrine carcinoma of the breast. [[H&E stain]]. | ||
| Synonyms = | | Synonyms = | ||
| Micro = apocrine morphology (cells with prominent [[nucleoli]] - may be multiple, abundant granular eosinophilic cytoplasm) - must be >=90% of tumour, loss of basal cells | | Micro = apocrine morphology (cells with prominent [[nucleoli]] - may be multiple, abundant granular eosinophilic cytoplasm) - must be >=90% of tumour, loss of basal cells | ||
| Line 25: | Line 25: | ||
| Rads = | | Rads = | ||
| Endoscopy = | | Endoscopy = | ||
| Prognosis = | | Prognosis = poor, worse the ductal carcinoma | ||
| Other = | | Other = | ||
| ClinDDx = | | ClinDDx = other breast masses | ||
| Tx = | | Tx = excision | ||
}} | }} | ||
'''Apocrine carcinoma of the breast''' is a rare form of [[invasive breast cancer]]. | '''Apocrine carcinoma of the breast''' is a rare form of [[invasive breast cancer]]. | ||
| Line 34: | Line 34: | ||
==General== | ==General== | ||
*Need >=90% apocrine morphology.<ref name=Ref_BP217>{{Ref BP|217}}</ref> | *Need >=90% apocrine morphology.<ref name=Ref_BP217>{{Ref BP|217}}</ref> | ||
*Worse prognosis that [[invasive ductal carcinoma of the breast]] in a large series.<ref name=pmid23245877>{{Cite journal | last1 = Dellapasqua | first1 = S. | last2 = Maisonneuve | first2 = P. | last3 = Viale | first3 = G. | last4 = Pruneri | first4 = G. | last5 = Mazzarol | first5 = G. | last6 = Ghisini | first6 = R. | last7 = Mazza | first7 = M. | last8 = Iorfida | first8 = M. | last9 = Rotmensz | first9 = N. | title = Immunohistochemically defined subtypes and outcome of apocrine breast cancer. | journal = Clin Breast Cancer | volume = 13 | issue = 2 | pages = 95-102 | month = Apr | year = 2013 | doi = 10.1016/j.clbc.2012.11.004 | PMID = 23245877 }}</ref> | |||
==Microscopic== | ==Microscopic== | ||
| Line 46: | Line 47: | ||
*Cutaneous Apocrine Carcinoma | *Cutaneous Apocrine Carcinoma | ||
***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum. | ***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum. | ||
*Apocrine-like carcinoma - immunoprolife doesn't fit for invasive AC (ER +ve, PR +ve, AR-ve).<ref name=pmid23245877/> | |||
===Images=== | ===Images=== | ||
| Line 66: | Line 68: | ||
*ER -ve. | *ER -ve. | ||
*PR -ve. | *PR -ve. | ||
*often | *often HER2 +ve but can be HER2 -ve<ref name=pmid19898421>{{Cite journal | last1 = Niemeier | first1 = LA. | last2 = Dabbs | first2 = DJ. | last3 = Beriwal | first3 = S. | last4 = Striebel | first4 = JM. | last5 = Bhargava | first5 = R. | title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. | journal = Mod Pathol | volume = 23 | issue = 2 | pages = 205-12 | month = Feb | year = 2010 | doi = 10.1038/modpathol.2009.159 | PMID = 19898421 }}</ref> | ||
Notes | Notes | ||